Fw: (LML) the Maltalep study- Harm after SDR prophylaxis

 

 

Leprosy Mailing List – March 19,  2020

Ref.: (LML)  the Maltalep study- Harm after SDR prophylaxis

From:  Diana Lockwood, Barbara de Barros and Steve Walker, London

---

 

Dear Pieter,

 

We discussed the increase in MB leprosy cases that occurred in a trial of single dose Rifampicin (SDR) and BCG, the MALTALEP trial on the LML in Oct 2019.   This trial shows no significant protection against leprosy by SDR.

 

We have now published our comments as a letter in International Journal of Infectious Diseases 2020. We attach the link to the paper. https://doi.org/10.1016/j.ijid.2020.01.054

 

Since there is now evidence of harm in giving SDR as prophylaxis against leprosy we suggest that there should be further discussions about the use of this intervention.

 

 

Diana Lockwood

Barbara de Barros

Steve Walker

 

Clinical Research Department, London School of Hygiene & Tropical Medicine, London UK

 

---

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/82532e26-e82f-44bd-a897-db78f5b95688%40googlegroups.com.